Literature DB >> 18573817

Memory decline evolves independently of disease activity in MS.

B Duque1, J Sepulcre, B Bejarano, L Samaranch, P Pastor, P Villoslada.   

Abstract

BACKGROUND: The natural history of cognitive impairment in multiple sclerosis (MS) and its relationship with disease activity is not well known. In this study, we evaluate a prospective cohort of 44 MS patients who were followed every 3 months for 2 years. Cognitive evaluation was done at baseline and by the end of the study using the Brief Repeatable Battery-Neuropsychology. Clinical evaluation included assessment of new relapses and changes in disability (Extended Disability Status Scale (EDSS)) confirmed at 6 months.
RESULTS: We found that verbal memory performance deteriorates after 2 years in patients with MS. These changes were observed in stable and active patients both in terms of relapses and disability progression, even at the beginning of the disease, and in patients with or without cognitive impairment at study entry. Attention and executive functions measured with the symbol digit modality test (SDMT) declined after 2 years in patients with confirmed disability progression. Furthermore, SDMT performance correlated with the EDSS change.
CONCLUSIONS: Our findings indicate that verbal memory steadily declines in patients with MS from the beginning of the disease and independently of other parameters of disease activity.

Entities:  

Mesh:

Year:  2008        PMID: 18573817     DOI: 10.1177/1352458508089686

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily.

Authors:  Francesco Patti; Alessandra Nicoletti; Silvia Messina; Elisa Bruno; Salvatore Lo Fermo; Graziella Quattrocchi; Clara Grazia Chisari; Davide Maimone; Sabina Cilia; Mario Zappia
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

2.  Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.

Authors:  Maria Sepúlveda; Begoña Fernández-Diez; Elena H Martínez-Lapiscina; Sara Llufriu; Nuria Sola-Valls; Irati Zubizarreta; Yolanda Blanco; Albert Saiz; Dino Levy; Paul Glimcher; Pablo Villoslada
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

3.  Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Authors:  Yvonne Benešová; Aleš Tvaroh
Journal:  Ther Adv Neurol Disord       Date:  2016-10-21       Impact factor: 6.570

Review 4.  Cognitive impairment in multiple sclerosis.

Authors:  Jesus Lovera; Blake Kovner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.

Authors:  Giulia DiGiuseppe; Mervin Blair; Sarah A Morrow
Journal:  Int J MS Care       Date:  2018 Jul-Aug

6.  Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study.

Authors:  Karine Baumstarck-Barrau; Marie-Claude Simeoni; Françoise Reuter; Irina Klemina; Valérie Aghababian; Jean Pelletier; Pascal Auquier
Journal:  BMC Neurol       Date:  2011-02-02       Impact factor: 2.474

7.  NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis.

Authors:  José A G Agúndez; Elena García-Martín; Carmen Martínez; Julián Benito-León; Jorge Millán-Pascual; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Laura Turpín-Fenoll; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecillas; José Francisco Plaza-Nieto; Félix Javier Jiménez-Jiménez
Journal:  BMC Neurol       Date:  2014-04-23       Impact factor: 2.474

8.  Vitamin D3 receptor ( VDR ) gene rs2228570 (Fok1) and rs731236 (Taq1) variants are not associated with the risk for multiple sclerosis: results of a new study and a meta-analysis.

Authors:  Elena García-Martín; José A G Agúndez; Carmen Martínez; Julián Benito-León; Jorge Millán-Pascual; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Laura Turpín-Fenoll; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecillas; José Francisco Plaza-Nieto; Félix Javier Jiménez-Jiménez
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

9.  LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis.

Authors:  Elena García-Martín; Oswaldo Lorenzo-Betancor; Carmen Martínez; Pau Pastor; Julián Benito-León; Jorge Millán-Pascual; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Laura Turpín-Fenoll; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecillas; Elena Lorenzo; José Francisco Plaza-Nieto; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  BMC Neurol       Date:  2013-04-10       Impact factor: 2.474

10.  Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.

Authors:  Francesco Patti; Vincenzo Brescia Morra; Maria Pia Amato; Maria Trojano; Stefano Bastianello; Maria Rosalia Tola; Salvatore Cottone; Andrea Plant; Orietta Picconi
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.